Royalty Pharma plc (NASDAQ:RPRX – Get Rating) Director Mario Germano Giuliani sold 154,986 shares of the firm’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $41.72, for a total value of $6,466,015.92. Following the completion of the sale, the director now directly owns 22,890,000 shares of the company’s stock, valued at approximately $954,970,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Mario Germano Giuliani also recently made the following trade(s):
- On Monday, September 19th, Mario Germano Giuliani sold 232,185 shares of Royalty Pharma stock. The stock was sold at an average price of $41.50, for a total value of $9,635,677.50.
- On Wednesday, September 7th, Mario Germano Giuliani sold 261,881 shares of Royalty Pharma stock. The stock was sold at an average price of $42.66, for a total value of $11,171,843.46.
- On Thursday, August 25th, Mario Germano Giuliani sold 500 shares of Royalty Pharma stock. The stock was sold at an average price of $44.00, for a total value of $22,000.00.
Royalty Pharma Stock Down 1.5 %
RPRX opened at $41.02 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 19.22 and a quick ratio of 19.22. The stock has a market capitalization of $24.91 billion, a price-to-earnings ratio of 53.27, a price-to-earnings-growth ratio of 1.11 and a beta of 0.30. The business has a 50-day moving average of $43.03 and a two-hundred day moving average of $41.49. Royalty Pharma plc has a 12 month low of $34.86 and a 12 month high of $44.75.
Royalty Pharma Dividend Announcement
Institutional Trading of Royalty Pharma
A number of institutional investors have recently modified their holdings of RPRX. Advisor Group Holdings Inc. grew its holdings in shares of Royalty Pharma by 22.5% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,899 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 716 shares during the period. Envestnet Asset Management Inc. purchased a new stake in shares of Royalty Pharma during the 4th quarter worth about $253,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Royalty Pharma during the 4th quarter worth about $207,000. Dimensional Fund Advisors LP grew its holdings in shares of Royalty Pharma by 43.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 230,201 shares of the biopharmaceutical company’s stock worth $9,174,000 after purchasing an additional 69,686 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Royalty Pharma by 26.1% during the 4th quarter. Principal Financial Group Inc. now owns 38,089 shares of the biopharmaceutical company’s stock worth $1,518,000 after purchasing an additional 7,873 shares during the period. Hedge funds and other institutional investors own 54.94% of the company’s stock.
Analyst Upgrades and Downgrades
RPRX has been the subject of several research reports. Citigroup lifted their price target on Royalty Pharma from $50.00 to $60.00 in a research note on Thursday, July 28th. Morgan Stanley lifted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Monday, August 8th. UBS Group started coverage on Royalty Pharma in a research report on Monday, June 13th. They set a “buy” rating and a $47.00 price objective for the company. Finally, Tigress Financial lifted their price objective on Royalty Pharma from $52.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.43.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.